IO BIOTECH INC. - COMMON STOCK

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

21 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces 2023 Third Quarter Results

13 11 2023 07:12:16 提供 Nasdaq GlobeNewswire

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

13 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

10 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

08 11 2023 15:30:00 提供 Nasdaq GlobeNewswire

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

01 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

23 10 2023 00:00:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 10 2023 15:30:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

12 9 2023 07:05:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

06 9 2023 07:35:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces 2023 Second Quarter Results

11 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

IO Biotech Appoints Heidi Hunter to its Board of Directors

11 8 2023 07:05:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

08 8 2023 07:05:00 提供 Nasdaq GlobeNewswire

IO Biotech, Inc. Announces $75 Million Private Placement Financing

07 8 2023 07:30:12 提供 Nasdaq GlobeNewswire

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

28 7 2023 07:05:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

25 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

18 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

14 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

01 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

IO Biotech to Present at the Jefferies Healthcare Conference

30 5 2023 15:35:00 提供 Nasdaq GlobeNewswire